Article Details
Retrieved on: 2021-10-04 06:45:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AstraZeneca said Enhertu demonstrated a 72% reduction in the risk of disease progression or death. "This is the second BTD for Enhertu in breast cancer and now ...
Article found on: www.lse.co.uk
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here